Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mecamylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 4/20 | 1.00 |
| ▸ | CHRNB4 known ✓ | P30926 | 4/20 | 1.00 |
| ▸ | CHRNA3 known ✓ | P32297 | 4/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 3/20 | 1.00 |
| ▸ | CHRNG | P07510 | 3/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 3/20 | 1.00 |
| ▸ | CHRND | Q07001 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | CHRNE | Q04844 | 1/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmecamylamine SCHEMBL29376444 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| 2(R)-Mecamylamine SCHEMBL308575 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL3008785 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL11028235 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL34253 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL4416036 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL7208020 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL34252 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL2896995 | 0.97 | CHRNB2 (0.95) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Mecamylamine SCHEMBL5633212 | 0.97 | CHRNB2 (0.95) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040591-B2 | Methods and compositions comprising at least one α3 βA4 nAChR antagonist or pharmaceutically acceptable salt thereof | AGI THERAPEUTICS PUBLIC LIMITED COMPANY (IE) | 2015-05-26 | — | — | US | claimed |
| US-20130030057-A1 | METHODS AND COMPOSITIONS COMPRISING AT LEAST ONE ALPHA3 BETA4 nAChR ANTAGONIST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AGI THERAPEUTICS LIMITED | 2013-01-31 | — | — | US | claimed |
| US-20100196479-A1 | METHODS AND COMPOSITIONS COMPRISING AT LEAST ONE ALPHA3 BETA4 nAChR ANTAGONIST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AGI THERAPEUTICS LIMITED | 2010-08-05 | — | — | US | claimed |
| US-9040591-B2 | Methods and compositions comprising at least one α3 βA4 nAChR antagonist or pharmaceutically acceptable salt thereof | AGI THERAPEUTICS PUBLIC LIMITED COMPANY (IE) | 2015-05-26 | — | — | US | disclosed |
| US-20130030057-A1 | METHODS AND COMPOSITIONS COMPRISING AT LEAST ONE ALPHA3 BETA4 nAChR ANTAGONIST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AGI THERAPEUTICS LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20100196479-A1 | METHODS AND COMPOSITIONS COMPRISING AT LEAST ONE ALPHA3 BETA4 nAChR ANTAGONIST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | AGI THERAPEUTICS LIMITED | 2010-08-05 | — | — | US | disclosed |
| US-20080207766-A1 | METHODS AND COMPOSITIONS FOR TREATING AT LEAST ONE UPPER GASTROINTESTINAL SYMPTOM | AGI THERAPEUTICS RESEARCH LTD. | 2008-08-28 | — | — | US | disclosed |
| EP-1603544-B1 | TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO 2.2.1 HEPTAN-2-AMINE | AGI THERAPEUTICS RES LTD (IE) | 2007-10-10 | — | — | EP | disclosed |
| US-20070224284-A1 | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof | DEVANE JOHN | 2007-09-27 | — | — | US | disclosed |
| EP-1603544-A1 | TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO 2.2.1 HEPTAN-2-AMINE | AGI Therapeutics Ltd. (IE) | 2005-12-14 | — | — | EP | disclosed |
| US-20040209961-A1 | Treatment of intestinal conditions with N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine | AGI THERAPEUTICS LIMITED (IE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004080446-A1 | TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO[2.2.1]HEPTAN-2-AMINE | AGI THERAPEUTICS LTD. (US) | 2004-09-23 | — | — | WO | disclosed |